Cargando…
Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
Most patients with metastatic hormone sensitive prostate cancer will progress to metastatic castration-resistant prostate cancer (mCRPC); Finding a highly effective, safe treatment with low recurrence rate has important clinical implications. Herein, we present a case of a 65-year-old man with castr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206126/ https://www.ncbi.nlm.nih.gov/pubmed/37234981 http://dx.doi.org/10.3389/fonc.2023.1177941 |
_version_ | 1785046159097593856 |
---|---|
author | Zhao, Dongsheng Su, Wen Zeng, Liang Hu, Guoqian Tang, Jin |
author_facet | Zhao, Dongsheng Su, Wen Zeng, Liang Hu, Guoqian Tang, Jin |
author_sort | Zhao, Dongsheng |
collection | PubMed |
description | Most patients with metastatic hormone sensitive prostate cancer will progress to metastatic castration-resistant prostate cancer (mCRPC); Finding a highly effective, safe treatment with low recurrence rate has important clinical implications. Herein, we present a case of a 65-year-old man with castration-resistant prostate cancer treated by multi-protocol exploration. Magnetic resonance imaging (MRI) revealed prostate cancer invading the bladder, seminal vesicle glands, and peritoneum with pelvic lymph node metastasis. Transrectal B ultrasound puncture of prostate tissue was performed, and the pathological diagnosis was prostatic adenocarcinoma. CTC (Circulating tumor cell) gene test was performed in peripheral blood, and the result showed BRCA1 gene mutation. The patient died of tumor complications after trying docetaxel combined with cisplatin chemotherapy, PARP inhibitor (nilaparib), PD-1 inhibitor (tislelizumab) and other treatments. This patient showed that the selection of an individualized combination chemotherapy regimen based on genetic testing results benefited the patient’s tumor control. When choosing a treatment regimen, problems such as failure to respond to re-chemotherapy and resistance to nilaparib may lead to deterioration of the condition. |
format | Online Article Text |
id | pubmed-10206126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102061262023-05-25 Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review Zhao, Dongsheng Su, Wen Zeng, Liang Hu, Guoqian Tang, Jin Front Oncol Oncology Most patients with metastatic hormone sensitive prostate cancer will progress to metastatic castration-resistant prostate cancer (mCRPC); Finding a highly effective, safe treatment with low recurrence rate has important clinical implications. Herein, we present a case of a 65-year-old man with castration-resistant prostate cancer treated by multi-protocol exploration. Magnetic resonance imaging (MRI) revealed prostate cancer invading the bladder, seminal vesicle glands, and peritoneum with pelvic lymph node metastasis. Transrectal B ultrasound puncture of prostate tissue was performed, and the pathological diagnosis was prostatic adenocarcinoma. CTC (Circulating tumor cell) gene test was performed in peripheral blood, and the result showed BRCA1 gene mutation. The patient died of tumor complications after trying docetaxel combined with cisplatin chemotherapy, PARP inhibitor (nilaparib), PD-1 inhibitor (tislelizumab) and other treatments. This patient showed that the selection of an individualized combination chemotherapy regimen based on genetic testing results benefited the patient’s tumor control. When choosing a treatment regimen, problems such as failure to respond to re-chemotherapy and resistance to nilaparib may lead to deterioration of the condition. Frontiers Media S.A. 2023-05-10 /pmc/articles/PMC10206126/ /pubmed/37234981 http://dx.doi.org/10.3389/fonc.2023.1177941 Text en Copyright © 2023 Zhao, Su, Zeng, Hu and Tang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhao, Dongsheng Su, Wen Zeng, Liang Hu, Guoqian Tang, Jin Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review |
title | Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review |
title_full | Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review |
title_fullStr | Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review |
title_full_unstemmed | Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review |
title_short | Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review |
title_sort | multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with brca mutations: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206126/ https://www.ncbi.nlm.nih.gov/pubmed/37234981 http://dx.doi.org/10.3389/fonc.2023.1177941 |
work_keys_str_mv | AT zhaodongsheng multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview AT suwen multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview AT zengliang multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview AT huguoqian multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview AT tangjin multiprotocolexploratorytreatmentformetastaticcastrationresistantprostatecancerwithbrcamutationsacasereportandliteraturereview |